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Running heading: Changes in practice after publication of an RCT 
  
What is known about this topic? 
 
 Changing clinical practice for existing clinicians usually entails a long lag time. 
 Evidence from adequately powered, well-designed, randomized controlled trials can 
inform practice in palliative care 
 Octreotide is widely used in the management of inoperable malignant bowel obstruction 
around the world on the basis of a number of small studies, all but one of which were 
underpowered 
 
What this paper adds: 
 
 This paper demonstrates that high quality clinical evidence from effectiveness (real-world) 
studies is assimilated by many clinicians practicing in palliative medicine 
 Uptake varies by clinician factors that can be identified in the population (age, previous 
use of octreotide) 
 
Implications for practice, theory or policy: 
 
 This paper demonstrates that it is important to examine the uptake of new knowledge into 
practice 
 One way of tracking the influence of a paper is to ask clinicians if they changed practice as a 
result of a new study with findings directly applicable to their practice.  
 Clinician surveys are important in order to understand changes in knowledge and attitudes, 






Translating research evidence into clinical practice often has a long lag time. 
 
Aim 
To determine the impact of a phase III randomised controlled trial on palliative care clinicians’ 
self-reported practice change.  
 
Design 
Online survey about use of octreotide in managing inoperable malignant bowel obstruction due to 
cancer or its treatments distributed in November, 2016, two years after the first publication of the 
study in a peer-reviewed journal. Demographic, self - reported practice and the reasons under-
pinning this were collected. Responses were aggregated to ‘practice modified’ or ‘practice not 
modified’. A multinomial regression model explored predictors of practice change. 
 
Setting 
Members of the Australian New Zealand Society of Palliative Medicine. 
 
Results 
Response rate was 20.8% (106/509): 55.6% were aged >50; 56.5% female; 77% had previously 
prescribed octreotide for this clinical indication. 52/106 (49.1%) modified practice (60.9% of those 
who had previously prescribed octreotide in this setting). In those who reported practice change, most 
frequently octreotide was now used when other therapies failed; for not changing practice ‘more 
confirmatory evidence was needed’ was most often cited. 
 
In the regression model, older age (clinician age 50-59 (RR 0.147 (95% CI 0.024, 0.918; p 0.04) and 
having practices with lower proportions of people treated with octreotide (0-20%; RR 0.039 (95%CI 
0.002, 0.768; p 0.033) predicted greater self-reported practice change. 
 
Conclusion 
Clinician-reported change in practice in the survey is seen in the majority of respondents. This 




Incorporating clinical trial evidence into clinical practice is challenging. Many strategies have been 





 engaging local key opinion leaders
3 and educational material, each with 
varying success in changing practice. Even though each requires significant resources, these 
approaches only manage to shift routine practice minimally. 
1-3 
 
The translation of research evidence into practice is lengthy, regardless of the field of clinical 
practice. Estimates suggest that, on average, 17 years will elapse before research is fully incorporated 
into routine clinical care.
4 This significant lag time is unacceptable to patients, funders and policy 
makers, and requires more effective ways of bringing new knowledge to the bedside. Early adopters 
of new evidence are part of the spectrum of uptake of new knowledge and this paper sought to 
identify those clinicians who reported that their practice had changed in response to the findings of an 
adequately powered phase III study.  
 
Malignant bowel obstruction secondary to cancer or its treatment  is a relatively common problem 
amongst patients with advanced cancer (3-15%).
5
 The prognosis of inoperable bowel obstruction is 
poor and is often associated with difficult to control vomiting (often faeculent), abdominal pain and 
distension. When surgical intervention is deemed inappropriate, treatment seeks to minimise 
symptoms, including reducing the volume and frequency of vomiting. 
 
To date, there has been no standardized clinical approach to managing vomiting in inoperable bowel 
obstruction due to cancer or its treatments. One systematic review suggested that there was potential 
benefit from the use of dexamethasone
6 to aid resolution of bowel obstruction, and theoretical benefit 
from the use of ranitidine to reduce the volume of upper gastro-intestinal secretions.
7
 Octreotide has 
previously been prescribed widely for symptomatic treatment in inoperable bowel obstruction due to 
cancer or its treatments without empiric evidence. This incomplete evidence base led the Australian 
national Palliative Care Clinical Studies Collaborative (PaCCSC)
8 to investigate the net effects of 
octreotide or placebo on inoperable bowel obstruction due to cancer or its treatments in an adequately 
powered multi-site phase III study. 
 
This RCT was conducted across 12 Australian specialist palliative care services with a primary end 
point of days free of vomiting at 72 hours. The study’s results did not demonstrate any statistically or 
clinically significant difference between groups, confirmed by other studies of somatostatin analogues 
conducted simultaneously.
9 Further, the participants receiving octreotide had a statistically significant 
increase in the use of hyoscine butylbromide, the protocol-defined treatment for people with colicky 
abdominal pain. The survey was to quantify clinicians’ response to these new findings in the short 
term (two years after the publication of the results) with expectation that there would be a range from 
no response from changes in practice through to maintaining the status quo. 
 
Few studies to date have demonstrated the short term changes in s e l f - r e p o r t e d  clinical practice 
as a result of such a study. In addition to publication in a peer-reviewed journal and presentation of 
findings at international conferences, an article was prepared for the Australian and New Zealand 
Society of Palliative Medicine’s newsletter. The aim of this current survey was to determine whether 
this phase III study had influenced clinicians’ self-reported knowledge and attitudes or behaviours. 
Participants were palliative care specialists or trainees in Australasia surveyed two years after 




The results from the octreotide RCT were first presented at an international conference in June 2012. 
This paper was published online as a peer-reviewed publication in November 2014 and, 
subsequently, in the printed edition in May 2015. 
 
Survey 
Australasian palliative care clinicians’ utilisation of octreotide in the management of inoperable 
bowel obstruction due to cancer or its treatments was explored in an online survey in Australasia in 
November, 2016. This was the only issues explored in this survey. One email reminder was sent out 
two weeks after the initial email invitation. The survey was sent by the Society to all Australian New 
Zealand Society of Palliative Medicine (ANZSPM) members working in palliative medicine or with a 
special interest in this field. The email linked to an online survey through a secured portal on 
CareSearch (www.caresearch.com.au). No pilot nor clinometric testing was done.  
The survey sought to assess any self-reported changes in clinicians’ pharmacological management of 
inoperable bowel obstruction due to cancer or its treatments in response to this phase III RCT. Of 
note, no details about the trial nor its results were given in the survey. Basic demographic information 
about the clinician and information about his/her previous and current prescribing practices of 
octreotide were gathered. Options for response about any change to practice (positive or negative) 
were aggregated to ‘practice modified’ or ‘practice not modified’ and could include no change or 
increased use of octreotide. 
Analysis 
Data were summarised descriptively. A sub-group of particular interest was consultant physicians 
who had previously prescribed octreotide for the symptomatic treatment of inoperable bowel 
obstruction due to cancer or its treatments and provided responses. A multinomial regression model 
was used to explore the relationship between respondent characteristics and practice change and to 
identify any factors to identify factors increasing the likelihood of practice modification. 
 
No data were imputed. Data were collated in Excel spreadsheets (Excel 2010, Microsoft, Seattle, 
Washington, USA. 2010) and analysed in SPSS (Version 23.0, IBM Corp, Armonk, New York, USA. 
2014) 
 
Ethics approval and reporting 
Ethics approval was granted by the Social Behavioural Research Ethics Committee, Flinders 
University, Adelaide, South Australia. Given that the audience for the survey was established medical 
practitioners, an information sheet was sent with the web link, and participation taken as informed 
consent. The results are presented using the studies Strengthening the Reporting of Observational 
studies in Epidemiology (STROBE) framework for reporting observational data and the Checklist for 





In total, 20.8% (106/509) of members of ANZSPM in November, 2016 responded. Of note given 
their roles as local key opinion leaders, 88 respondents were consultants in palliative medicine, 
representing 41.3% of the estimated consultant workforce nationally in palliative care.12 Over half of 
respondents were aged over 50 years (55.6%) and were female (56.6%). The respondents covered 
medical practitioners with a range of clinical seniority and time commitment to clinical care (Table 
1). The majority of respondents worked more than 0.81 of a full time equivalent (FTE) role  (72/106 
(68%)). Seventy seven percent of respondents had previously used octreotide for the treatment of 
inoperable bowel obstruction due to cancer or its treatments. 
 
One half of all the respondents (52/106; 49.1%) indicated practice change (Table 2) as a result of 
incorporating the results of the study into their clinical work. When the analysis was limited to 
palliative care consultants who had prescribed octreotide previously, this proportion increased to 
60.9% (42/69) of respondents. In those who indicated practice modification, the most frequent 
response was that ‘octreotide was now only used when other therapies had failed’ (35/106; 33.0%). 
The most frequently cited reason for not modifying practice was that ‘more confirmatory evidence 
was needed’ (21/106; 19.8%), followed by practitioners being convinced of the benefit from their 
own observations (15/106; 14.2%). 
Indication of practice modification by age of prescriber who had previously prescribed octreotide for 
inoperable bowel obstruction due to cancer or its treatments differed (Table 3 ; p=0.027) but not in 
those who previously prescribed octreotide less frequently for this indication (Table 4; p=0.165). In 
the regression model with practice change as the dependent variable, adjusting for sex and full time 
equivalent roles, older age (relative risk clinician age 50-59 (RR 0.147 (95% CI 0.024, 0.918; p 0.04) 
and having a practice where a lower proportion of people were already treated with octreotide (0-20% 
of patients with inoperable bowel obstruction due to cancer or its treatments; RR 0.039 (95%CI 
0.002, 0.768; p 0.033) predicted greater likelihood of indicating practice change. The model was 
statistically significantly better than an intercept only model and explained 33.4% of the variance. 
(p=0.023; McFadden R-square 0.334). 
Discussion 
Given the relatively small number of people who present with inoperable bowel obstruction due to 
cancer or its treatments and the subjective nature of the responses, above all, this survey provides 
important insights into the self -reported practice of  palliative practitioners who treat 
people with malignant bowel obstruction. The level of   reported   practice modification 
within a two year timeframe from the publication of an adequately powered, multi-site, placebo  
controlled study of octreotide for inoperable bowel obstruction due to cancer or its treatments is 
clinically significant, given the overall change achieved with targeted interventions for existing 
practitioners.1-3 Many clinicians reported modified practice within a relatively short period of time.  
With 77.4% of clinicians reporting having used octreotide for this indication previously, changing 
knowledge and attitudes in 60.9% of previous prescribers suggests the likelihood of real changes to 
clinical practice.  A sizable proportion of clinicians who self-reported prescribing octreotide in this 
clinical setting indicated that their practices would not change. 
 
A large number of practitioners did not respond, and it cannot be estimated what their knowledge, 
attitudes or current practice is. Even if the 52 people who indicated practice change were the only 
people to change within the potential respondent group of 509, this would still mean that at least 
10.2% (52/509) of clinicians had modified their practice in response to new data from the cited phase 




Given that the natural history of untreated inoperable bowel obstruction due to cancer or its treatments 
is poorly described in the clinical literature and an objective outcome measure was used in the phase 
III RCT, the placebo arm describes the natural history of bowel obstruction in this clinical setting, and 
provides evidence of the additional effects (benefits and harms) that can be directly attributed to 
octreotide. The response rate in both arms was equal, so it is interesting to see that practitioners who 
did not change practice did so because they themselves had attributed benefit to octreotide when they 
had prescribed it. 
The results should be interpreted in the light of one other key publication in the palliative  care 
literature.
9  The paper by Obita et al systematically reviewed the clinical trial evidence for the net 
effects of somatostatin analogues in the symptomatic treatment  of inoperable bowel obstruction due 
to cancer or its treatments and may also  have  had an impact on clinicians’ responses to the  survey  
given that the Obita paper was published electronically in September 2016, two months before the 
survey. 
For 
There are barriers to the uptake of results from adequately powered RCT into day-to-day clinical 
practices. The response from some clinicians seeking further research before implementing changes in 
prescribing practices is interesting given the paucity of evidence in favour of octreotide in this clinical 
setting to date. Individual personal beliefs in the value of certain therapies may be more difficult to 




Due to a number of factors, engaging clinicians in research surveys is difficult. Demographic 
information about the total ANZSPM membership such as sex and age distribution was unavailable to 
make comparisons between those who did and did not respond to the survey. The results only reflect 
the self-reported practice (itself a limitation without objective corroboration) and does not reflect the 
self-reported practice of nurse practitioners (who have pharmaceutical prescribing rights), 




These results were gathered from a trans-national professional body of clinicians and the results 
provide responses from a diverse cross section of the medical practitioners most commonly 
prescribing octreotide in palliative care patients. The level of modification to clinical practice 
reported in this survey is greater than the effect of the practice change studies that are part of the 
Cochrane reviews of key opinion leaders, audit and feedback and academic detailing. 
Implications for clinical practice 
It is encouraging that many clinicians have assimilated this new knowledge into their clinical 
knowledge and attitudes. The self-reported changes in practice are not radical, but where new 
effectiveness data become available, many palliative care clinicians indicated that this impacts on 
their practice. 
This survey assesses self-reports of clinicians’ knowledge and attitudes to prescribing octreotide for 
inoperable bowel obstruction due to cancer or its treatments. Access to real-time prescribing data 
from clinical settings where octreotide is u s e d  for this clinical indication would help to corroborate 
these findings. Understanding the continued trends in practice change (and whether the changes 
described here are sustained) are important future questions. 
Conclusion 
The results of this survey reflect real change in knowledge and attitudes in practitioners as a result of 
an adequately powered phase III effectiveness RCT. Uptake of the results into practice varied 
between practitioners with age and previous prescribing habits predictors of change. The findings 
support the need for expanding good quality clinical research in palliative medicine, a specialty 
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Octreotide Online Survey questions   
What age are you?        
What is your sex?          
What is your principle medical role?     
Are you a registrar?        
What Full Time equivalent (FTE) hours do you work?            
Have you ever prescribed octreotide?    
Are you aware of the randomised control trial assessing the use of 
octreotide in malignant bowel obstruction published in the Journal 
of Pain and Symptom Management in May 2015?   
 
Prior to becoming aware of this trial did you ever use octreotide in 
the management of malignant bowel obstruction?  
 
Malignant bowel obstruction.  In what context do you prescribe 
octreotide?   
 
Other.  In what context do you prescribe octreotide?   
What percentage of patients with malignant inoperable bowel 
obstruction and vomiting do you treat with octreotide? 
 
Have you prescribed octreotide in the last year?   
How many people do you estimate you prescribed octreotide for in 
an average year? 
 
What dose of octreotide, in a twenty four period, would you most 
commonly prescribe? 
 
Do you use an infusion or divided doses of octreotide?    
On average, how long would you administer octreotide for to 
determine whether it was beneficial for the patient?  
 
Has the trial changed your prescribing practices with regards to 
octreotide prescribing in the setting of malignant bowel 
obstruction?  
 
Please tick the statements which apply to you.   
Since becoming aware of the trial I prescribe octreotide less often   
Since becoming aware I never prescribe octreotide in the context of 
malignant bowel obstruction  
 
Since becoming aware of the trial I prescribe a lower dose of 
octreotide   
 
Since becoming aware of the trial I only prescribe octreotide when 
other treatments have failed 
 
Since becoming aware of the trial I am more selective in the patients 
in whom I prescribe octreotide 
 
Since becoming aware of the trial I prescribe a higher dose of 
octreotide  
 
Since becoming aware of the trial I prescribe octreotide more 
frequently  
 
Please tick the statements that apply to you     
I have not changed my practice because there is a lack of alternative 
therapeutic options 
 
I have not changed my practice because I believe the trial was not of 
sufficient quality  
 
I have not changed my practice because  I believe more 
confirmatory evidence is required 
 
I have not changed my practice because  the population I treat is 
different than that of the study  
 
I have not changed my practice because I am convinced of the 
benefit from my own observations 
 
 
